Oxford Biomedica PLC Result of AGM (8009D)

TIDMOXB

RNS Number : 8009D

Oxford Biomedica PLC

23 June 2023

Oxford Biomedica

Result of Annual General Meeting

Oxford, UK - 23 June 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company") , a quality and innovation-led viral vector CDMO , announces today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held at 3pm on 23 June 2023 in Oxford. As proposed in the Notice of AGM, all resolutions were decided by poll vote.

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Company's website at www.oxb.com

Copies of the document setting out the above resolutions passed at the 2023 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism

On the Record Date (21 June 2023) there were 96,521,209 ordinary shares of 50 pence each in issue, each carrying one vote per share.

 
 
                                         Votes 
                                      For (incl. 
               Resolution                votes        % of                     % 
                                        at the        votes                   of                      Total 
                                      Chairman's      cast       Votes       votes       Votes        votes 
                                      discretion)               Against      cast      Withheld*       cast     Result 
 
      Ordinary resolutions 
     --------------------------------------------  --------  -----------  --------  ------------  -----------  ------- 
 
      To receive the 
       Company's Accounts, 
       the Reports 
       of the Directors 
       and Auditor 
       and the Strategic 
       Report for the 
       year ended 31 
 1     December 2022.                73,060,750     100.00%      629        0.00%      146,857     73,061,379    PASS 
     ----------------------------  --------------  --------  -----------  --------  ------------  -----------  ------- 
      To receive the 
       Directors' Remuneration 
       Report and the 
       Report of the 
       Auditor on the 
       Remuneration 
       Report for the 
       year ended 31 
 2     December 2022.                51,080,127     79.93%    12,826,613   20.07%     9,301,496    63,906,740    PASS 
     ----------------------------  --------------  --------  -----------  --------  ------------  -----------  ------- 
      To appoint Dr. 
       Frank Mathias 
 3     as a Director.                73,062,102     99.81%     137,244      0.19%       8,890      73,199,346    PASS 
     ----------------------------  --------------  --------  -----------  --------  ------------  -----------  ------- 
      To appoint Leone 
       Patterson as 
 4     a Director.                   72,892,590     99.58%     307,356      0.42%       8,290      73,199,946    PASS 
     ----------------------------  --------------  --------  -----------  --------  ------------  -----------  ------- 
      To reappoint 
       Dr. Roch Doliveux 
 5     as a Director.                67,536,075     92.26%    5,662,468     7.74%       9,693      73,198,543    PASS 
     ----------------------------  --------------  --------  -----------  --------  ------------  -----------  ------- 
      To reappoint 
       Professor Dame 
       Kay Davies as 
 6     a Director.                   66,057,059     90.24%    7,141,705     9.76%       9,472      73,198,764    PASS 
     ----------------------------  --------------  --------  -----------  --------  ------------  -----------  ------- 
      To reappoint 
       Stuart Paynter 
 7     as a Director.                72,551,391     99.11%     649,338      0.89%       7,507      73,200,729    PASS 
     ----------------------------  --------------  --------  -----------  --------  ------------  -----------  ------- 
      To reappoint 
       Stuart Henderson 
 8     as a Director.                66,051,339     90.25%    7,139,682     9.75%      17,215      73,191,021    PASS 
     ----------------------------  --------------  --------  -----------  --------  ------------  -----------  ------- 
      To reappoint 
       Dr. Heather 
       Preston as a 
 9     Director                      64,485,621     88.10%    8,713,178    11.90%       9,437      73,198,799    PASS 
     ----------------------------  --------------  --------  -----------  --------  ------------  -----------  ------- 
      To reappoint 
       Robert Ghenchev 
 10    as a Director.                73,059,336     99.81%     140,259      0.19%       8,641      73,199,595    PASS 
     ----------------------------  --------------  --------  -----------  --------  ------------  -----------  ------- 
      To reappoint 
       Dr. Michael 
       Hayden as a 
 11    Director.                     67,826,937     92.66%    5,371,827     7.34%       9,472      73,198,764    PASS 
     ----------------------------  --------------  --------  -----------  --------  ------------  -----------  ------- 
      To reappoint 
       Catherine Moukheibir 
 12    as a Director.                68,240,515     93.22%    4,959,431     6.78%       8,290      73,199,946    PASS 
     ----------------------------  --------------  --------  -----------  --------  ------------  -----------  ------- 
      To reappoint 
       Namrata P. Patel 
 13    as a Director.                73,140,356     99.92%      59,590      0.08%       8,290      73,199,946    PASS 
     ----------------------------  --------------  --------  -----------  --------  ------------  -----------  ------- 
      To appoint 
      PriceWaterhouseCoopers 
 14   LLP as auditor.                73,193,707     99.99%      7,290       0.01%       7,239      73,200,997    PASS 
     ----------------------------  --------------  --------  -----------  --------  ------------  -----------  ------- 
      To authorise 
       the Directors 
       to agree the 
       remuneration 
 15    of the auditor.               73,195,908     99.99%      4,776       0.01%       7,552      73,200,684    PASS 
     ----------------------------  --------------  --------  -----------  --------  ------------  -----------  ------- 
      To authorise 
       the Directors 
 16    to allot shares.              70,498,713     96.31%    2,702,643     3.69%       6,880      73,201,356    PASS 
     ----------------------------  --------------  --------  -----------  --------  ------------  -----------  ------- 
 
                   Special resolutions 
     --------------------------------------------  --------  -----------  --------  ------------  -----------  ------- 
      To authorise 
       the Directors 
       to disapply 
       pre-emption 
 17    rights.                       72,202,544     98.64%     996,404      1.36%       9,288      73,198,948    PASS 
     ----------------------------  --------------  --------  -----------  --------  ------------  -----------  ------- 
      To authorise 
       the Directors 
       to further disapply 
       pre-emption 
       rights for acquisitions 
       and specified 
 18    capital investments.          70,474,362     96.28%    2,721,812     3.72%      12,062      73,196,174    PASS 
     ----------------------------  --------------  --------  -----------  --------  ------------  -----------  ------- 
      To permit the 
       Directors to 
       convene general 
       meetings (other 
       than annual 
       general meetings) 
       on not less 
       than 14 days' 
 19    notice.                       71,049,162     97.06%    2,150,941     2.94%       8,133      73,200,103    PASS 
     ----------------------------  --------------  --------  -----------  --------  ------------  -----------  ------- 
 

* A vote withheld is not a vote in law and is not counted towards votes cast in respect of a resolution.

In addition, further to the announcement by the Company in January, Dr. Siyamak Rasty has stepped down from the Company's Board of Directors with effect from the conclusion of today's AGM.

The Board recognises that, whilst resolution 2 was passed with a clear majority at almost 80%, there was also a significant vote against this resolution. The Board will seek to engage with those shareholders who voted against this resolution and it is anticipated that a revised remuneration policy will be presented to shareholders for their approval at the Company's AGM in 2024. In accordance with the UK Corporate Governance Code, an update on the views received from shareholders and details of any further actions taken by the Company will be published no later than 23 December 2023 by way of Stock Exchange Announcement. A summary will also be published in the 2023 Annual Report and Accounts.

-Ends-

 
 
             Enquiries: 
 
 
             Oxford Biomedica plc: 
             Taylor Boyd, VP, Head of IR - T: [phone]/ E: [e-mail] 
             Sophia Bolhassan, VP, Corporate Affairs and IR - T: +44 (0) 
             7394 562 425 / E: [e-mail] 
 
             Consilium Strategic Communications: 
             T: [phone] / E: [e-mail] 
             Mary-Jane Elliott / Matthew Neal / Davide Salvi 
 

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and a US-based subsidiary, Oxford Biomedica Solutions, based near Boston, MA, US. Learn more at www.oxb.com , www.oxbsolutions.com , and follow us on LinkedIn , Twitter and YouTube .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGSESFMDEDSEDM

(END) Dow Jones Newswires

June 23, 2023 12:32 ET (16:32 GMT)